Celecoxib-Cervical Cancer Relationship Analysis via In Vitro and Mendelian Randomization

A May 2026 dataset by Tongfei Wang presents results from a multi-method study investigating the anticancer role of celecoxib. The data likely contains results from in vitro assays, network pharmacology, and Mendelian randomization analyses linking NEU1 inhibition to cervical cancer risk. The dataset is licensed under CC-BY-4.0 and hosted on figshare.

Use Cases

• Validate drug efficacy hypotheses based on in vitro assay results for cell proliferation, migration, and invasion.
• Explore causal relationships in drug-target pathways based on Mendelian randomization results.
• Analyze immune cell mediation effects based on the reported CD25 on CD45RA+ CD4+ non-regulatory T cell mediation percentage.
• Identify potential therapeutic targets based on network pharmacology and enrichment analysis highlighting T-cell-related pathways.

Strengths

• Integrates results from three distinct methodological approaches: in vitro experiments, network pharmacology, and Mendelian randomization.
• Provides a specific causal inference result: genetically proxied NEU1 inhibition reduced cervical cancer risk (OR = 0.736, 95% CI: 0.566–0.958).
• Includes a quantified mediation effect: CD25 on CD45RA+ CD4+ non-regulatory T cells mediated 28.458% of the total effect.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (11.4 KB), indicating limited scope and likely summary-level results rather than raw experimental data.

Provenance

Source

figshare

Collection Method

Results from in vitro assays (Cell Counting Kit-8, wound-healing, colony-formation, transwell), network pharmacology, enrichment analyses, and Mendelian randomization.

Freshness

Last updated 2026-05-19 05:41:45; freshness should be verified.